Trade Axogen Inc - AXGN CFD

AxoGen, Inc. Company profile

About AxoGen Inc

Axogen, Inc. is focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers Axotouch Two-Point Discriminator, used to measure the innervation density of any surface area of the skin. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which can range from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its portfolio of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AxoGen Inc revenues increased 13% to $127.4M. Net loss increased 13% to $27M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administative increase from $24.1M to $70.6M (expense), Research and development increase of 35% to $24.2M (expense).

Equity composition

Common Stock $.01 Par, 03/11, 15M auth., 4,305,026 issd. Insiders control approx. 36.43%. Public Offering: 12/86, 1,288,000 shares @ $4 by John G. Kinnard Investments. 7/94, 7/93 & 7/92, 5% stock dividend. 9/05/01, Company changed its FYE from June to Dec. FY 6/01, 12/01 Summ. Q's reflect the reclassification. FY'02 Q's are CLA.